EHA 2022 | Safety & efficacy of nelarabine, pegylated asparaginase and venetoclax in frontline therapy of T-ALL
Farhad Ravandi
• 11 Jun 2022
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, comments on the safety and efficacy of nelarabine, pegylated asparaginase, and venetoclax in the frontline treatment of T-cell acute lymphoblastic leukemia (T-ALL). Dr Ravandi explains that the combination of nelarabine and pegylated asparaginase is well tolerated, but venetoclax can only be added for 1-2 cycles as it is myelosuppressive. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding – BMS/Celgene, Amgen, Astex/Taiho, Syros, Prelude, Abbvie, Xencor Consultant – BMS, Abbvie, Novartis, AstraZeneca, Taiho, Jazz
